The study, conducted by researchers at Vanderbilt University Medical Center, examined clinical records from 65 children with IDD who were referred to a behavioral sleep medicine clinic between June 2018 and January 2023. The children ranged in age from 20 months to 18 years, with a mean age of 5.8 years. Three-quarters had autism spectrum disorder recorded in their charts, while others carried diagnoses of developmental, global, or speech delay, attention deficit hyperactivity disorder, or Trisomy 21. Most presented with more than one diagnosis, reflecting the clinical complexity that makes sleep management in this population so challenging.

The intervention itself was deliberately compact. Each family attended a 90-minute initial appointment, either in person or by telehealth, during which a psychologist trained in community-based sleep education conducted a detailed behavioral sleep assessment. Rather than handing out generic sleep hygiene advice, the psychologist drew individualized recommendations from 12 possible categories, spanning morning routines, daytime light exposure, bedroom use, exercise, caffeine avoidance, nap management, bedtime routines, bedroom environment, a

The follow-up structure of the clinic deserves particular attention because it illustrates how a brief intervention can be embedded into routine clinical care rather than functioning as a stand-alone research protocol. Families typically returned one to three months after the initial appointment, with an average interval of about two and a half months, to review what had worked, what had not, and where implementation had stalled. This spacing is consistent with behavioral consultation models in which a single well-constructed plan is given time to take hold before adjustments are made. Additional visits could be scheduled at one- to six-month intervals when needed, and the psychologist maintained a closed loop of communication with the referring developmental medicine or sleep medicine clinician, sharing progress and surfacing medical questions that might otherwise go unaddressed. That bidirectional flow of information is a defining feature of the collaborative model and may partly explain why caregivers reported feeling motivated to describe barriers honestly rather than presenting an overly favorable picture of their adherence.

The measurement approach also reflects the pragmatic realities of clinical record review. Rather than relying solely on standardized sleep diaries or actigraphy, the investigators evaluated clinical notes using a modified version of the Pediatric Sleep and Autism Clinical Global Impressions Scale, an adaptation of a clinician-rated measure designed to capture meaningful change in sleep within this population. Caregiver report served as the primary source of outcome information, which is standard practice in pediatric behavioral sleep research given that young children, and particularly children with IDD, cannot reliably self-report sleep patterns. The trade-off is that such reports are vulnerable to recall and expectancy effects, a limitation the authors implicitly acknowledge by framing the work as a record review of feasibility and effectiveness rather than a controlled trial.

The central statistical finding underscores how tightly outcome was bound to adherence. Among caregivers who reported following the individualized recommendations at the first follow-up, 85 percent described significant improvement in their child’s sleep. Among those who reported non-compliance, only 20 percent described improvement. The association between compliance and improvement was highly significant by both Pearson chi-square and Fisher’s exact test, with a p-value below 0.0001. While the direction of causality in such observational data cannot be definitively established, the magnitude of the difference is striking and aligns with a long-standing principle in behavioral sleep medicine: behavioral interventions for pediatric insomnia are active treatments that require the caregiver to change routines, environments, and responses to night waking. A plan that is not implemented cannot plausibly produce its intended effects, and the near fourfold difference in improvement rates between compliant and non-compliant families is consistent with that interpretation.

It is worth situating these results within the broader evidence base for behavioral sleep treatment in children with neurodevelopmental conditions. Prior randomized trials and parent-training studies in autism spectrum disorder have demonstrated improvements in sleep onset latency, reduced prolonged night wakings, and better sleep efficiency, and some have documented collateral gains in daytime behavior, including reductions in inattention, hyperactivity, and daytime sleepiness. A systematic review of parent training embedded in behavioral sleep interventions for autism and IDD concluded that such training is generally effective and valued by families. The present study extends this literature by demonstrating that the core elements of those structured, multi-session programs can be distilled into a brief consultative format delivered within an academic medical center, reaching families who were referred through ordinary clinical channels rather than recruited through research advertisements.

The individualized nature of the recommendations is central to why a single 90-minute encounter could plausibly be effective. Behavioral sleep treatment for children with IDD is not a one-size-fits-all prescription; it is a process of functional assessment followed by tailored modification of the conditions that maintain insomnia. For a toddler whose bedtime routine is chaotic, the plan might emphasize a predictable, visually supported sequence of pre-sleep activities. For a school-age child with anxiety-driven bedtime resistance, the plan might involve graduated exposure or reinforcement systems. For a child taking medications with alerting effects, the plan might coordinate timing adjustments with the prescribing clinician. The twelve recommendation categories described in the clinic’s framework, from morning light exposure and exercise to caffeine avoidance, nap management, and bedroom environment, map onto the established mechanisms by which sleep hygiene and behavioral strategies entrain circadian rhythms, build appropriate sleep pressure, and create discriminable cues that signal sleep onset. The emphasis on adapting these strategies with visual supports and reinforcement systems, and on identifying smaller incremental changes that move toward ideal recommendations, reflects the recognition that families of children with IDD often face constraints that make textbook recommendations impractical as first steps.

The referral pathway described in the study also carries practical significance for other institutions considering similar models. Before referral, medical providers were asked to exclude or address medical contributors to sleep disturbance, such as obstructive sleep apnea, gastroesophageal reflux, and seizures, either before or concurrently with the behavioral referral. This gatekeeping step is clinically important because insomnia symptoms in children with IDD can be the presenting manifestation of an underlying medical condition, and behavioral treatment alone would be insufficient in such cases. At the same time, the model permitted referral while medical workup was still in progress, avoiding delays for families waiting on sleep studies or other evaluations. This balance between medical diligence and timely access to behavioral care is a recurring challenge in pediatric sleep medicine, and the collaborative structure, in which the psychologist communicates findings back to the medical team, offers one template for managing it.

The demographic profile of the sample, with roughly two-thirds of children under the age of seven, mirrors the epidemiology of behavioral insomnia in this population, where bedtime resistance and night waking most commonly prompt referral during the preschool and early school years. The inclusion of adolescents, though a smaller proportion, is notable because sleep problems in adolescents with IDD are often complicated by shifting circadian phase, psychotropic medication use, and increasing autonomy around screen use and bedtime, all of which require modified behavioral strategies. The collection of data on psychotropic medications and sleep-related surgical interventions in the record review suggests awareness of these overlapping influences, even though the brief report does not detail their effects on outcomes.

Several limitations temper the strength of the conclusions and point toward future research. The absence of a control group means that natural remission, regression to the mean, and concurrent medical treatments cannot be ruled out as contributors to reported improvement. The reliance on caregiver report at a single follow-up interval leaves open questions about durability of gains beyond one to three months. The sample was drawn from a single academic medical center with a psychologist who had thirteen years of experience in IDD-related sleep care, raising questions about generalizability to community settings with less specialized staffing. Selection bias is also possible, since referring providers were asked to identify families open to behavioral intervention, which may have enriched the sample for motivated caregivers. Nonetheless, the very high compliance rate of 85 percent at first follow-up is itself a finding worth emphasizing, because it suggests that a single well-tailored session, delivered by a clinician with expertise in both behavioral sleep principles and the specific needs of children with IDD, can mobilize families to act. If replicated in larger, controlled, multi-site studies with objective sleep measures and longer follow-up, this model could offer a scalable answer to a persistent access problem: families of children with IDD frequently wait months or years for specialized behavioral sleep services, and a brief, collaborative education model embedded in existing medical care represents a pragmatic step toward closing that gap.

Subject of Research: Behavioral sleep education for children with intellectual and developmental disabilities

Article Title: Feasibility and effectiveness of a clinical model of sleep education for children with IDD: a record review

Article References: Malow, B. A., Fitzpatrick, K. A., & Loring, W. A. (2026). Feasibility and effectiveness of a clinical model of sleep education for children with IDD: a record review. Frontiers in Sleep, 5, Article 1937989. https://doi.org/10.3389/frsle.2026.1937989

Image Credits: AI Generated

DOI: 10.3389/frsle.2026.1937989

Keywords: sleep education, intellectual and developmental disabilities, pediatric insomnia, autism spectrum disorder, behavioral intervention, caregiver compliance, telehealth, sleep hygiene, clinical global impressions, Vanderbilt University Medical Center, collaborative care, record review

The relationship between light and sleep is rooted in fundamental human biology. The suprachiasmatic nucleus of the hypothalamus, the body’s master circadian clock, receives direct input from specialized retinal cells that are particularly sensitive to short-wavelength blue light. Evening and nighttime exposure to this light suppresses melatonin secretion from the pineal gland, delays circadian phase, and increases alertness at precisely the hours when the brain should be winding down. In the general population, these effects are well documented, and sleep hygiene guidelines routinely recommend dark, quiet bedrooms. What had been missing, the researchers note, is evidence specifically addressing whether nighttime light is associated with sleep quality in schizophrenia—a population in which circadian rhythm abnormalities, medication effects, and lifestyle factors all complicate the picture.

To fill that gap, the team designed a study that combined objective and subjective measurement in a way few investigations in this population have done. Each participant wore a wrist actigraphy device continuously for seven days. Actigraphy uses an accelerometer to detect movement, allowing researchers to estimate sleep onset, sleep offset, total sleep time, sleep efficiency, sleep onset latency, and wakefulness after sleep onset without relying on a patient’s recall. Because people with schizophrenia may have difficulty accurately reporting their own sleep, this objective component carries particular weight.

The researchers did not stop at the wrist, however. A portable photometer was placed beside each participant’s bed to independently measure ambient nighttime illuminance in lux, providing an environmental reading separate from the light that might reach the actigraphy sensor itself. Participants also kept a sleep diary recording bedtime and rising time, and subjective sleep quality was assessed with the Pittsburgh Sleep Quality Index, a widely used questionnaire covering sleep over the previous month. Median nighttime illuminance was 1.4 lux as measured by actigraphy and 4.1 lux as measured by the bedside photometer—levels far below ordinary indoor lighting but comparable to a dim nightlight or light leaking through curtains from streetlamps.

After statistically adjusting for a long list of potential confounders—including age, sex, smoking status, body mass index, psychiatric symptom severity, daytime light exposure, sleep timing, day length, and medications—the differences between light-exposure groups were striking. Compared with participants in the lowest nighttime-light group, those in the highest group showed 10 percent lower sleep efficiency, slept 55.6 minutes less in total, took longer to fall asleep, and spent 31 minutes more awake after sleep onset. Higher exposure to blue light specifically showed similar associations, consistent with the known sensitivity of the circadian system to short wavelengths.

One of the most intriguing findings is what the study did not show. The Pittsburgh Sleep Quality Index, which asked patients to rate their sleep over the preceding month, revealed no significant association with nighttime light. The researchers offer two possible explanations. First, some patients may experience objectively poorer sleep without fully recognizing it, a dissociation between perceived and measured sleep that has been described in other clinical populations. Second, the two measurement windows differ: the questionnaire retrospectively covers a month, while actigraphy and light measurements were collected prospectively over just seven days, a design that reduces recall bias but captures a shorter slice of life.

“Our findings suggest that even relatively low levels of nighttime light may be linked to measurable sleep disruption in people with schizophrenia,” said Mr. Ryota Miyake, a student researcher in the Department of Psychiatry at Fujita Health University School of Medicine who led the work with Dr. Yuichi Esaki, alongside Dr. Nakao Iwata, Dr. Tsuyoshi Kitajima, and Dr. Kiyoshi Fujita of Okehazama Hospital.

The clinical implications could be significant precisely because the exposure is so easy to modify. Poor sleep in schizophrenia is not a trivial side complaint: it is associated with worse quality of life, more severe psychiatric symptoms, impaired cognition, and reduced daily functioning, and it may contribute to relapse risk. Current management often leans on sedating medications, which carry their own burden of daytime drowsiness, metabolic effects, and drug interactions. If darker bedrooms genuinely improve sleep, a simple environmental adjustment—dimming screens, blocking streetlight with blackout curtains, or eliminating unnecessary nightlights—could offer a low-cost, nonpharmacological complement to existing treatment.

The authors are careful, however, to frame the results as an association rather than proof of cause and effect. The study was cross-sectional, meaning light exposure and sleep were measured at the same time, so it cannot determine whether light disrupts sleep or whether some other factor—such as underlying circadian dysfunction, greater nighttime activity, or differences in living environment—drives both. People who sleep poorly may also get up during the night and turn on lights, reversing the presumed direction of the relationship. Prospective intervention studies, in which bedrooms are deliberately darkened and sleep is tracked before and after, will be needed to establish causality.

“Optimizing the nighttime light environment could become an important part of sleep hygiene if future longitudinal and intervention studies confirm these findings,” said Mr. Miyake. If those trials succeed, the consequences could extend well beyond individual bedrooms. Lighting practices in psychiatric hospitals, group homes, and residential care facilities could be redesigned to protect patients’ sleep, potentially improving symptoms and daytime functioning while reducing reliance on additional sedating drugs. For now, the study stands as a reminder that the environment surrounding a sleeping person is not neutral—and that for one of psychiatry’s most vulnerable populations, even a few lux of stray light may be one factor worth taking seriously.

Subject of Research: The association between nighttime light exposure and objectively measured sleep parameters in outpatients with schizophrenia

Article Title: Nighttime light may disrupt sleep in people with schizophrenia

Article References: Nighttime light may disrupt sleep in people with schizophrenia. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: schizophrenia, sleep, nighttime light, actigraphy, circadian rhythm, sleep efficiency, blue light, Psychiatry Research, Fujita Health University, sleep hygiene, melatonin, observational study

The study, conducted by a team of clinicians at the Affiliated Hospital of North Sichuan Medical College in Nanchong, China, enrolled 120 patients who had been transferred from the ICU to general wards between June 2025 and September 2025 and who reported clinically significant sleep disturbances. The trial was prospectively registered with the Chinese Clinical Trial Registry, and all participants provided written informed consent under ethics approval from the hospital. Participants were randomly assigned in equal numbers to two groups, a design that allows researchers to isolate the specific effect of the new therapy from the benefits of routine care.

The control group received what many hospitals would consider standard treatment: the hypnotic drug eszopiclone, a non-benzodiazepine sedative commonly prescribed for insomnia, combined with routine sleep hygiene education, the practical advice about caffeine, light exposure, and bedtime routines that clinicians typically offer. The intervention group received the same pharmacological foundation but added a three-month program of internet-based cognitive behavioral therapy, or ICBT. This approach adapts the well-established principles of in-person cognitive behavioral therapy for insomnia to a digital format, allowing patients to work through therapeutic modules online at their own pace while submitting sleep diaries that track their progress.

Cognitive behavioral therapy for insomnia differs fundamentally from sleeping pills in how it targets the disorder. Rather than acting on brain chemistry to induce drowsiness, it works on the behaviors and thought patterns that sustain sleeplessness: irregular sleep schedules, excessive time in bed awake, catastrophic beliefs about the consequences of a bad night, and conditioned arousal in the bedroom. For ICU survivors, these mechanisms are particularly relevant, because the abnormal environment of critical care, with its constant light, noise, and frequent monitoring, can entrench deeply disrupted sleep patterns that then persist through learned association long after the physical threats have resolved.

The researchers assessed outcomes at three time points: baseline before treatment began, immediately after the three-month intervention, and again one month later, four months after baseline. They used a battery of validated instruments, including the Pittsburgh Sleep Quality Index and the Insomnia Severity Index to measure sleep, the Hamilton Anxiety and Depression Rating Scales to capture mood symptoms, and the 36-Item Short Form Health Survey to evaluate overall quality of life. This combination allowed the team to examine not just whether patients slept better, but whether the therapy rippled outward into their emotional and functional recovery.

The results were strikingly consistent for most outcomes. At both the end of the intervention and at follow-up, the group receiving ICBT showed significantly greater improvements than the control group in sleep quality, insomnia severity, depressive symptoms, and quality of life scores. The only exception was anxiety: the between-group difference in Hamilton Anxiety scores was not statistically significant immediately after the three-month program, but emerged at the one-month follow-up, suggesting that the emotional benefits of the therapy may take longer to consolidate than its direct effects on sleep.

Perhaps the most clinically consequential finding concerned medication. The rate of reduction in sleep medication was significantly higher in the intervention group than among patients receiving drugs alone. For a population already burdened by the pharmacological intensity of critical care, where sedatives, analgesics, and other agents accumulate during an ICU stay, the prospect of tapering hypnotic medication while maintaining or improving sleep represents a substantial advantage. It points toward a model of care in which digital therapy does not merely complement drugs but gradually replaces them.

The trial also provided encouraging data on adherence, often the Achilles heel of digital health interventions. Patients in the ICBT group showed good completion rates for the online modules and submitted sleep diaries reliably, while the control group demonstrated good acceptance of education and compliance with medication. An exploratory analysis of the intervention group’s diary data revealed significant within-group improvements over time in three objective-sounding sleep parameters: sleep efficiency, the proportion of time in bed actually spent asleep; sleep onset latency, how long it takes to fall asleep; and wake after sleep onset, the amount of time spent awake during the night. These are precisely the metrics that insomnia clinicians target most directly.

The significance of the study lies partly in its population. Post-intensive care syndrome, the cluster of physical, cognitive, and psychological impairments that follows critical illness, has become a major focus of critical care medicine, yet sleep disturbance within it remains under-treated. Traditional face-to-face cognitive behavioral therapy is effective for insomnia but requires trained therapists, multiple clinic visits, and considerable time, resources that are scarce for patients navigating recovery from critical illness. An internet-based format sidesteps many of these barriers, delivering structured therapeutic content to patients who may have limited mobility, live far from specialist services, or feel too fragile for frequent hospital trips.

The trial has limits worth noting. It was conducted at a single hospital over a concentrated recruitment window, and the follow-up extended only one month beyond the end of treatment, leaving longer-term durability an open question. The sleep diary findings were exploratory and drawn from within-group comparisons rather than the randomized contrast. Even so, the pattern of results, sustained improvements in sleep, mood, and quality of life, alongside reduced reliance on hypnotic medication, offers a compelling case that digital cognitive behavioral therapy deserves a place in the aftercare of ICU survivors. As hospitals worldwide grapple with the growing population of critical illness survivors, this study suggests that the most effective prescription for their broken sleep may arrive not in a pill bottle, but through a screen.

Subject of Research: Efficacy of internet-based cognitive behavioral therapy for sleep disturbances in ICU survivors

Article Title: A randomized controlled trial of internet-based cognitive behavioral therapy for sleep disturbances in ICU survivors

Article References: Xia, Y., Yang, J., Ding, X., Lai, X., Yong, N., Liu, H., Ma, Y., & Cui, L. (2026). A randomized controlled trial of internet-based cognitive behavioral therapy for sleep disturbances in ICU survivors. BMC Psychology. https://doi.org/10.1186/s40359-026-05702-z

Image Credits: AI Generated

DOI: 10.1186/s40359-026-05702-z

Keywords: internet-based cognitive behavioral therapy, ICU survivors, sleep disturbances, insomnia, randomized controlled trial, eszopiclone, post-intensive care syndrome, sleep quality, depression, quality of life, sleep hygiene, digital health

The review, led by Hening Pujasari of Universitas Indonesia together with colleagues in Indonesia and Malawi, followed the PRISMA 2020 reporting guidelines and was prospectively registered with PROSPERO. The team searched ten electronic databases from their inception through October 2025, looking for both randomized and non-randomized studies that assessed sleep outcomes in people living with HIV using validated instruments. Those instruments included the Pittsburgh Sleep Quality Index, the Insomnia Severity Index, actigraphy, and polysomnography—the gold-standard laboratory measurement of sleep architecture. Two reviewers independently screened the records and extracted the data, a standard safeguard against individual judgment errors.

Methodological rigor was a defining feature of the analysis. Risk of bias was assessed with design-appropriate tools: the Cochrane RoB 2.0 instrument for randomized trials and Joanna Briggs Institute tools for other study designs. Importantly, the authors judged bias domain by domain rather than collapsing everything into a single score, which preserves the nuance that a trial might be well-conducted overall yet vulnerable in one specific area such as blinding or outcome measurement. Eleven studies ultimately met the eligibility criteria, spanning a diverse array of interventions and comparison conditions.

That diversity posed a genuine analytical challenge. Because the eleven studies differed substantially in how their comparator groups were structured and which outcome instruments they used, the researchers restricted quantitative pooling a priori to studies with comparable controlled post-intervention Pittsburgh Sleep Quality Index data. Only three randomized trials—by Molavi and colleagues in 2020, Qi and colleagues in 2024, and Wen and colleagues in 2025, together enrolling 187 participants—met that comparability threshold. These were combined using a random-effects model, the standard approach when true effect sizes are assumed to vary across studies rather than being identical.

The pooled result was striking. The standardized mean difference, expressed as Hedges g, came out at −1.38 with a 95 percent confidence interval of −1.78 to −0.99, and heterogeneity was modest at I² = 27.5 percent. In plain terms, the interventions improved subjective sleep quality by an amount conventionally considered large, and the variation between studies was relatively low. Because only three trials were pooled, the team also ran a Hartung-Knapp sensitivity analysis, which is better suited to small numbers of studies than the default methods. That check produced a wider but still statistically significant interval of −2.31 to −0.48, reinforcing confidence in the direction of the effect even under conservative assumptions.

The authors went further with robustness testing. A leave-one-out analysis, in which the pooled estimate is recalculated after omitting each study in turn, retained both the direction and the statistical significance of the effect no matter which single trial was excluded. This is a meaningful safeguard in small meta-analyses, where a single influential study can sometimes drive the entire result. With only three pooled studies, however, publication bias could not be reliably assessed—a limitation the researchers acknowledge explicitly, since small meta-analyses are precisely the setting in which unpublished negative trials are hardest to detect.

Not all the evidence could be pooled. One study used a mixed pharmacological comparator, and several others reported outcomes with instruments other than the Pittsburgh Sleep Quality Index, so these were synthesized narratively rather than merged into the quantitative estimate. This decision reflects a growing consensus in evidence synthesis: forcing heterogeneous studies into a single pooled number can produce a deceptively precise figure that obscures real clinical differences. By pre-specifying their pooling criteria, the authors traded breadth of quantification for integrity of the estimate they did report.

Why does sleep matter so much in HIV care? The review’s background notes that sleep disturbances among people living with HIV are associated with poorer quality of life, suboptimal adherence to antiretroviral therapy, and adverse clinical outcomes. Adherence is particularly critical: consistent daily medication is what keeps viral load suppressed and prevents drug resistance. A patient who sleeps badly may struggle with the energy, mood, and routine organization that adherence demands, creating a pathway from disturbed sleep to worse virological control. Interventions that improve sleep without adding drug interactions or side effects therefore carry substantial public health potential, especially since they are described as scalable and low-risk.

The interventions represented in the eligible studies spanned several categories, including cognitive behavioural therapy for insomnia, brief behavioural treatment for insomnia, mindfulness-based cognitive therapy, emotional freedom techniques, and sleep hygiene training. The authors are careful not to crown a winner: with only three studies in the pooled analysis and considerable heterogeneity in intervention type, no single category can be established as superior. This is an honest reading of the data. Clinicians hoping for a definitive prescription—say, eight sessions of CBT-I over sleep hygiene pamphlets—will not find one here, and the authors explicitly say the findings should be regarded as preliminary pending larger, standardized trials.

What the review does establish is a foundation. It demonstrates that the question is answerable with rigorous methods, that subjective sleep quality as measured by the Pittsburgh Sleep Quality Index responds to non-pharmacological intervention in this population, and that future trials should standardize their outcome instruments and comparator structures so that their results can be combined. For the roughly thirty-eight million people living with HIV worldwide, many of whom report poor sleep, the message is cautiously encouraging: drug-free approaches appear to work, the effect may be large, and the research community now has a clear template for confirming it at scale.

Subject of Research: Non-pharmacological interventions for improving sleep quality in people living with HIV

Article Title: Non-pharmacological interventions to improve sleep quality among people living with HIV: a systematic review and meta-analysis

Article References: Pujasari, H., Putri, Y. S. E., Umar, E., Nurhayati, N., Friska, F., & Mulyana, A. S. (2026). Non-pharmacological interventions to improve sleep quality among people living with HIV: a systematic review and meta-analysis. BMC Public Health. https://doi.org/10.1186/s12889-026-29661-7

Image Credits: AI Generated

DOI: 10.1186/s12889-026-29661-7

Keywords: HIV, sleep quality, non-pharmacological interventions, systematic review, meta-analysis, PSQI, CBT-I, mindfulness, sleep hygiene, public health, antiretroviral therapy, insomnia